Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2013

View Archived Issues

Researchers present preclinical results for ML-297

Characterization and development of a potent inhibitor of cholesterol biosynthesis

Novel podophyllotoxin derivatives with significant antitumor activity presented

ACT-001 demonstrates efficacy and high oral bioavailability in vivo

Trial of gene therapy for Sanfilippo B syndrome begins

Suven presents a novel 5-HT6 receptor antagonist for the treatment of AD

New alpha-type CGRP receptor antagonists disclosed by Merck & Co.

Canadian group designs novel heteromultimer constructs for cancer

Healios and DSP sign Japanese joint development agreement for iPS-derived RPE cells

Vital Therapies enrolls first subject in Australia in phase III VTI-208 trial

FDA extends PDUFA date for Alprolix BLA

First patient treated in phase I/II HGB-205 study

FDA accepts Zalviso NDA for filing

Isis Pharmaceuticals earns milestone payment from GSK for ISIS-TTRRx

Actelion provides update on the DUAL program

NeurOp divulges novel NMDA receptor antagonists

Immunotherapeutic 3M-052 shows oncolytic potential

EMD Serono launches TocopheRx, a new spin-off focused on infertility treatment

Novel immunogenic peptide compositions presented by French group

ProJect Pharmaceutics signs agreement to develop new formulation of IMX-101

Novel CDK inhibitor unaffected by transporter-dependent drug resistance

Phase II all-oral combination study of simeprevir, TMC-647055 and samatasvir begins

PharmAthene terminates merger agreement with Theraclone Sciences

Baxter submits amended BLA for HyQvia

Forest Laboratories to acquire U.S. rights to Saphris

FDA grants orphan drug designation to Conatus' emricasan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...